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Abstract
Background: Cancer-related stigma attracts considerable research interest, but few studies have examined
stigmatisation in the healthy population. Qualitative studies suggest that stigma can discourage people from
attending cancer screening. We aimed to quantify the prevalence and socio-demographic patterning of cancer
stigma in the general population and to explore its association with cancer screening attendance.
Methods: In 2016, 1916 adults aged 18–70 years took part in home-based interviews in England. Measures assessed
demographic characteristics, self-reported screening uptake for cervical (n = 681), breast (n = 326) and colorectal
cancer (n = 371), and cancer stigma. Cancer stigma was measured with the validated Cancer Stigma Scale which
assesses six subdomains (Severity, Personal Responsibility, Awkwardness, Avoidance, Policy Opposition, and Financial
Discrimination), from which a mean score was calculated. Logistic regression analyses examined the association
between cancer stigma and having been screened as recommended versus not.
Results: Levels of cancer stigma were low, but varied across the six subdomains. Items regarding the severity of a cancer
diagnosis attracted the highest levels of agreement (30–51%), followed by statements about the acceptability of making
financial decisions on the basis of a cancer diagnosis such as allowing banks to refuse a mortgage (16–31%) and policy
opposition statements such as not having a responsibility to provide the best possible care for cancer patients (10–17%).
A similar proportion anticipated feeling awkward around someone with cancer (10–17%). Only 8–11% agreed with
personal responsibility statements, such as that a person with cancer is to blame for their condition, while 4–5% of adults
anticipated avoiding someone with cancer. Stigma was significantly higher in men (p < .05) and in those from ethnic
minority backgrounds (p < .001). Higher cancer stigma was associated with not being screened as recommended for all
three screening programmes (cervical: adjusted OR 1.59, 95% CI 1.15–2.20; breast: adjusted OR = 1.97, 95% CI 1.17–3.32;
colorectal: adjusted OR = 1.59, 95% CI 1.06–2.38).
Conclusions: Cancer stigma is generally low, but some aspects of stigma are more prevalent than others. Stigma is more
prevalent in certain population subgroups and is negatively associated with cancer screening uptake. These benchmark
findings may help track and reduce cancer stigma over time.
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Background
Despite recent improvements in treatment and survival,
cancer is still seen as a stigmatised disease. Cancer can
remind people of their own mortality and present un-
comfortable connotations of death and suffering, leading
to feelings of awkwardness and fear [1]. Indeed, recent
surveys show that a quarter of people in the UK believe
that a cancer diagnosis is a death sentence [2, 3], and
half of the population believes that cancer treatment is
worse than cancer itself [3].
Health-related stigma is defined as “a social process or
related personal experience characterised by exclusion, re-
jection, blame or devaluation that results from experience
or reasonable anticipation of an adverse social judgment
about a person or group identified with a particular health
problem” [4]. Although this definition emphasises the felt
experience of stigma by the stigmatised, stigma can be
studied in two ways: from the perspective of the stigmati-
sers (also referred to as “public” or “enacted” stigma) and
from the perspective of the stigmatised (i.e. “felt stigma”
or “self-stigma”) [1, 5, 6]. Most research into cancer stigma
thus far has focused on the latter, the stigma felt by cancer
patients, with the majority of studies examining stigma in
lung cancer patients [7–10]. These studies show that lung
cancer patients who are current or former smokers tend
to feel particularly stigmatised due to the perception that
their illness is self-inflicted and they are therefore to blame
for it [11].
Cancer stigma may not just affect cancer patients, but
public stigma of cancer may also negatively impact pub-
lic health efforts to reduce the burden of cancer in the
wider society. With 1 in 2 people born after 1960 in the
UK expected to develop some form of the disease during
their lifetime [12], cancer is high on the public health
agenda. However, exploratory work suggests that expec-
tations and fear of being stigmatised might discourage
some people from engaging in cancer prevention or
early detection because it may result in discovering you
belong to a stigmatised group [7, 13]. Various studies
have found that negative beliefs about cancer are indeed
associated with lower screening uptake [14, 15], lower
rates of self-examination for skin cancer [16], and higher
healthcare avoidance for fear of having the illness [17].
The hypothesis that stigma may deter help seeking for
illness is consistent with a number of studies in other
fields that have reported how anticipated stigma can im-
pede help seeking for mental health [18–21], sexual
health/HIV [22, 23], cirrhosis [24], and dementia [25].
Few studies have systematically explored public cancer
stigma. A study in more than five thousand cervical
screening-eligible women in Ireland found that mean an-
ticipated stigma scores for 8 items about HPV infection
were just below the midpoint (2.3 on a scale from 1 to
4), but were higher for those with lower levels of
education [26]. However, the scale consisted of various
stigma-related items, such as personal responsibility for
disease, avoidance, and disgust, and scores for individual
items were not reported, making it impossible to assess
whether there is variation in agreement across the items.
An online US survey that did report scores for individual
components of stigma found that agreement with state-
ments about personal responsibility for cancer were gen-
erally low (mean score 2.4 out of 7), agreement with
statements of societal responsibility for cancer were
mid-range (3.7/7), and that willingness to engage in vari-
ous prosocial cancer-related behaviours, such as donat-
ing money to a cancer charity, was relatively high (4.7/7)
[27]. However, the sample may not have been represen-
tative of the general US population (for example, more
than half reported college-degree level education, com-
pared with a 30% national average [28]), and results may
not be generalisable to other populations outside the US.
The Cancer Stigma Scale (CASS) is a validated scale
that was developed to measure the multiple dimensions
of cancer stigma in a non-patient population [29]. It has
six distinct domains: three factors relating to people’s
perceptions of cancer and three factors encompassing
social aspects and anticipated behaviour towards cancer
patients. Previous research has used the CASS to look at
stigma in the general population in the UK, but the data
were from an online panel, limiting the generalisability of
the findings [30]. This study aimed to i) assess prevalence
and socio-demographic patterning of cancer stigma in a
population-representative sample of English adults, and ii)
examine the association between cancer stigma and self-
reported uptake of breast, cervical, and colorectal cancer
screening in those eligible for screening.
Methods
Participants
Data were collected as part of the cross-sectional Atti-
tudes, Behaviour and Cancer UK Survey (ABACUS) in
2016, from which other studies have been published (e.g.
[31]). Adults aged 18–70 years (N = 2048) were eligible
to participate. We chose the lower age limit to ensure
maturity for informed consent to participate in the sur-
vey, while the upper age limit represents the age when
people cease being invited to cancer screening. Partici-
pants were recruited as part of the Kantar TNS omnibus
survey, during several waves in April and May 2016.
Kantar TNS is a market research agency that uses ran-
dom location sampling to recruit participants. The sam-
pling points are defined based on the 2011 census small
area statistics and postcode address file. Quotas are set
by Kantar TNS at each location for gender or housewife,
children in the household, and working status. Kantar
TNS also supplies weights to ensure population-
representativeness. Kantar TNS collects data for their
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omnibus survey using face-to-face home-based computer
assisted interviews. Ethical approval was granted by the
University College London (UCL) ethics committee (Pro-
ject ID Number: 5771/002). All participants gave verbal
consent at the start of the omnibus interview, which was
recorded on the TNS database as part of the interview.
Measures
Cancer stigma
Cancer stigma was measured using items from the Cancer
Stigma Scale (CASS) [29], a validated scale with 25 items
assessing six subdomains: Awkwardness, Severity, Avoid-
ance, Personal Responsibility, Policy Opposition and Finan-
cial Discrimination. Due to space restrictions we selected
18 items (3 per subscale), based on an online pilot survey
(n = 392) with quotas for age, gender and educational sta-
tus. In the pilot, we examined the item-total correlations
for the items in each subscale to assess possible redun-
dancy, and retained items with the highest correlation for
the main survey. Responses were recorded on a 6-point
Likert scale from ‘disagree strongly’ to ‘agree strongly’ and
reversed scored for 4 items, so that all scores were from 1
to 6 with higher scores indicating more stigma (see Table 2
for items that were reverse scored). For the descriptive sta-
tistics, we dichotomised the responses into “agree” (agree
slightly, agree moderately, and agree strongly) and “dis-
agree” (disagree slightly, disagree moderately, disagree
strongly) and present the percentage of people agreeing to
each item. In addition, we calculated mean scores for each
of the subscales (excluding those who had more than one
missing item on that subscale), as well as a total mean
score for all 18 items of the CASS (with those missing
more than 6 items excluded from analyses). The presenta-
tion of means for each subscale allows for the comparison
of our results with the original CASS development paper
[29]. Note that the scale as used in the current study mea-
sures stigma of cancer in general (i.e. as a group of dis-
eases), and is not specific to any one type of cancer.
In the present sample, internal reliability of the whole
scale (0.77, and 0.88 in the pilot) and four of the sub-
scales was somewhat lower than in the online pilot sur-
vey, but still adequate: avoidance (0.71, 0.90 in the pilot),
personal responsibility (0.74, 0.90 in the pilot), policy op-
position (0.71, also 0.71 in the pilot) and severity (0.71,
0.75 in the pilot). Despite good internal reliability for
these scales in the online pilot survey (financial discrim-
ination 0.82 and awkwardness 0.81), Cronbach’s alpha
was lower for financial discrimination (0.60) and awk-
wardness (0.57) in the current sample.
Cancer screening uptake
Cancer screening is offered via the National Health Ser-
vice (NHS) in England with eligibility based on age and
gender: breast: women aged 50–70; cervical: women
aged 25–64; colorectal (using the faecal occult blood
test): men and women aged 60–70. Past attendance at
cancer screening was self-reported and only asked to
those eligible for that screening programme at the time
of interview. Responses were dichotomised for analysis
as “screened as recommended” (i.e. those who had been
every time they were invited for that particular screening
programme) and “not screened as recommended” (i.e.
those who had not been every time they were invited
and those who had never been despite being eligible).
Those who refused to answer this question were coded
as missing.
Socio-demographics
Sociodemographic variables included age, gender, ethni-
city, and social grade. Ethnicity was assessed using the
2011 census question [32] recoded into “White” (any
white background) and “Black, Asian, and Minority Eth-
nic (BAME)”. Social grade was recoded into four cat-
egories using the National Readership Survey (NRS)
social grades, which are based on the occupation of the
household’s chief income earner “AB” (higher and inter-
mediate managerial, administrative and professional),
“C1” (supervisory, clerical and junior managerial admin-
istrative and professional), “C2” (skilled manual
workers), and “DE” (semi-skilled and unskilled manual
workers, and state pensioners, casual and lowest
workers, unemployed with state benefits only) [33].
Analyses
We excluded those with missing data on the sociodemo-
graphic variables and those with a previous diagnosis of
cancer or who refused to say whether they had previously
been diagnosed with cancer, because they were not asked
the questions about cancer stigma to avoid unnecessary
distress. For the analyses on screening uptake, we also ex-
cluded those with missing data on the uptake variables.
The sample characteristics are reported using weighted
and unweighted data. The percentage agreement with
each cancer stigma item, as well as mean scores per sub
scale, were reported using weighted data to help accur-
ately estimate prevalence. We then looked at the sociode-
mographic predictors of the total cancer stigma score
using linear regression analyses, both in univariable and
multivariable analyses adjusting for other sociodemo-
graphic variables (age, gender, ethnicity and social grade).
For those analyses, we used the unweighted data because
weights do not tend to alter the associations and using the
unweighted data is recommended because it is simpler
and reduces the risk of overfitting [34]. Finally, we exam-
ined the association between total cancer stigma score
and uptake of breast, cervical and colorectal cancer
screening using logistic regression analyses with the un-
weighted data, both unadjusted and adjusted for all socio-
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demographic variables. As a sensitivity analysis, we also ex-
amined the association between total cancer stigma score
and screening uptake, dichotomising the uptake variable as
“having never been screened” vs “having been screened at
least once”. All statistical analyses were carried out in SPSS
24, using a significance level of p < .05 to indicate statistical
significance, except for the sociodemographic associations
where we use p < .001 to allow for multiple testing.
Results
Sample characteristics
Overall 2048 adults completed the survey. Figure 1 shows
the number of participants excluded because of a cancer
diagnosis or missing data, which resulted in a sample of
1916 for analyses. Sample characteristics are displayed in
Table 1. Mean age of the weighted sample was 42.8 (SD =
15.3), about half (51%) were female, and the majority of
the sample were from a White ethnic background (84%).
About a quarter were from the highest social grade (AB;
27%), half were from the middle grades (C1: 28% and C2:
22%) and 23% belonged to the lowest grades (DE).
Cancer stigma
Completion rates, agreement with each cancer stigma
item and means for each sub scale using the weighted
sample are reported in Table 2. Completion rates for the
individual cancer stigma items were high at around 95%
of the sample. Levels of cancer stigma were low but var-
ied across the six sub scales. Items regarding the severity
of a cancer diagnosis attracted the highest levels of
agreement (30–51%; M = 3.08, SD = 1.07). This was
followed by statements about the acceptability of making
financial decisions on the basis of a cancer diagnosis,
such as allowing banks to refuse a mortgage, to which
16–31% agreed (M = 2.31, SD = 1.03). Policy opposition
statements were endorsed by 10–17% (M = 2.10, SD =
1.05), while a similar proportion (10–17%) would feel
awkward around someone with cancer (M = 1.85, SD =
0.95). Only 8–11% agreed with personal responsibility
statements, such as that a person with cancer is to blame
for their condition (M = 1.81, SD = 0.90), while 4–5% of
adults anticipated avoiding someone with cancer (M =
1.40, SD = 0.72).
Fig. 1 Flow chart of participant inclusion and exclusion
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Sociodemographic associations with cancer stigma
We examined the associations between sociodemo-
graphic variables and cancer stigma using the total can-
cer stigma score for the unweighted sample. For these
analyses, we excluded a further 93 participants (4.9%)
who had missing data on more than 6 items of the
CASS. Total cancer stigma scores in the remaining sam-
ple (N = 1823) were low (mean CASS score = 2.10 (out
of a possible 6), SD = 0.57; Table 1).
Linear regression analysis showed that higher stigma
scores were associated with being male (M= 2.15, SD 0.60
vs M = 2.06, SD 0.54; β = .077, p < .001) and being from an
ethnic minority background (M= 2.29, SD 0.64 vs M =
2.07, SD 0.55; β = .138, p < .001, for the multivariable ana-
lysis), both in univariable and multivariable analyses
adjusting for other sociodemographic variables. Stigma
was not significantly associated with age or social grade.
Association between cancer stigma and cancer screening
participation
The association between cancer stigma and self-reported
screening uptake was examined in the subgroups of
those with complete data on the sociodemographic, can-
cer stigma score, and cancer screening uptake variables
who were eligible for cervical (n = 681), breast (n = 326),
and colorectal (n = 371) cancer screening (see Fig. 2).
Overall, 26% of eligible participants were not screened
as recommended for cervical screening (n = 175), 18%
for breast screening (n = 57), and 33% for colorectal can-
cer screening (n = 124).
In unadjusted analyses, higher total cancer stigma was
significantly associated with increased odds of not being
screened as recommended for all three screening pro-
grammes: cervical OR = 1.71 95% CI: 1.25–2.34, p < .001;
breast OR = 2.12, 95% CI: 1.28–3.54, p < .01; and colo-
rectal cancer screening OR = 1.63, 95% CI: 1.10–2.42,
p < .05. These associations remained significant after
adjusting for all sociodemographic variables: cervical
OR = 1.59 95% CI: 1.15–2.20, p < .01; breast OR = 1.97,
95% CI: 1.17–3.32, p < .05; and colorectal cancer screen-
ing OR = 1.59, 95% CI: 1.06–2.38, p < .05 (see Fig. 2).
The results of the sensitivity analyses, examining the as-
sociation between cancer stigma and screening uptake of
those who had been screened at least once versus those
who had never been screened, were very similar and are
reported in the Additional file 1.
Discussion
This is the first population-representative study to show
that cancer stigma in English adults is generally low, but
Table 1 Unweighted and weighted sample characteristics, and unweighted sociodemographic associations of total CASS score
Unweighteda Weighteda Total Cancer Stigma Univariable Total Cancer Stigma Multivariablec
N = 1916 N = 1918 N = 1823 N = 1823
N (%)b N (%)b M (SD) d B (SE) d βd B (SE) d βd
Total sample 2.10 (0.57)
Age in years (M, SD) 43.0 (15.9) 42.8 (15.3)
18–34 703 (36.7) 681 (35.5) 2.11 (0.59)
35–54 648 (33.8) 731 (38.1) 2.11 (0.57) −.003 (.032) −.003 .006 (.032) .005
55–70 565 (29.5) 506 (26.4) 2.08 (0.55) −.035 (.033) −.028 −.007 (.034) −.005
Gender
Female 1025 (53.5) 971 (50.6) 2.06 (0.54)
Male 891 (46.5) 946 (49.4) 2.15 (0.60) .088 (.027) .077* .088 (.027) .077*
Ethnicity
White (Any) 1610 (84.0) 1614 (84.1) 2.07 (0.55)
BAME 306 (16.0) 304 (15.9) 2.29 (0.64) .225 (.037) .142* .219 (.037) .138*
Social grade
AB (high) 329 (17.2) 511 (26.7) 2.05 (0.56)
C1 551 (28.8) 537 (28.0) 2.08 (0.55) .023 (.040) .018 .014 (.040) .011
C2 420 (21.9) 428 (22.3) 2.10 (0.55) .046 (.043) .034 .046 (.042) .033
DE (low) 616 (32.2) 442 (23.0) 2.15 (0.61) .100 (.040) .082 .098 (.039) .080
BAME Black, Asian, and Minority Ethnic
*p < .001
a The weighted and unweighted sample sizes are unequal because weights were calculated based on the whole sample (N = 2048) before applying exclusions for
the current analyses
bUnless otherwise stated
c Adjusted for age, gender, ethnicity and social grade
d M mean, SD standard deviation, B unstandardized regression coefficient, SE standard error, β standardised regression coefficient
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Table 2 Completion rates and agreement with each of the cancer stigma items for the weighted sample (N = 1918)a
Completion rate
N (%)
Agree
N (%)
M (SD)b
Severity 3.08 (1.07)
Having cancer usually ruins a person’s career 1826 (95.2) 825 (45.2)
Getting cancer means having to mentally prepare oneself for death 1832 (95.5) 937 (51.1)
Cancer usually ruins close personal relationships 1830 (95.4) 547 (29.9)
Financial discrimination 2.31 (1.03)
It is acceptable for banks to refuse to make loans to people with cancer 1829 (95.4) 316 (17.3)
Banks should be allowed to refuse mortgage applications for cancer-related reasons 1826 (95.2) 285 (15.6)
It is acceptable for insurance companies to reconsider a policy if someone has cancer 1827 (95.3) 567 (31.0)
Policy opposition 2.10 (1.05)
More government funding should be spent on the care and treatment of those with cancer (R) 1824 (95.1) 1552 (85.1)
The needs of people with cancer should be given top priority (R) 1816 (94.7) 1500 (82.6)
We have a responsibility to provide the best possible care for people with cancer (R) 1832 (95.5) 1641 (89.6)
Awkwardness 1.85 (0.95)
I would feel comfortable around someone with cancer (R) 1829 (95.4) 1526 (83.4)
I would find it difficult being around someone with cancer 1824 (95.1) 174 (9.5)
I would find it hard to talk to someone with cancer 1826 (95.2) 204 (11.2)
Personal responsibility 1.81 (0.90)
A person with cancer is liable for their condition 1819 (94.8) 193 (10.6)
If a person has cancer it’s probably their fault 1828 (95.3) 139 (7.6)
A person with cancer is to blame for their condition 1824 (95.1) 160 (8.8)
Avoidance 1.40 (0.72)
I would feel angered by someone with cancer 1826 (95.2) 83 (4.5)
I would try to avoid a person with cancer 1831 (95.5) 79 (4.3)
If a colleague had cancer I would try to avoid them 1826 (95.2) 67 (3.7)
a(R) denotes items that were reverse coded for calculation of the mean scores
bM mean, SD standard deviation
Fig. 2 Unadjusted (left) and adjusted (right) odds ratios and 95% confidence intervals for not being screened as recommended (versus being
screened as recommended) by total CASS score (continuous)
Vrinten et al. BMC Cancer          (2019) 19:566 Page 6 of 10
is higher in men and those from ethnic minority back-
grounds and is negatively associated with cancer screening.
In addition, stigma varied by subdomain, with lowest en-
dorsement of statements regarding avoidance, awkward-
ness, and personal responsibility, but higher endorsement
of statements about policy opposition, acceptability of fi-
nancial discrimination and severity of a cancer diagnosis.
This was the first study to use the CASS in a
population-representative sample in the UK and thus
serves as a benchmark for cancer stigma in the general
population in England. Compared with the CASS devel-
opment paper (which used an online panel sample of a
similar age range and gender distribution in England in
2010, but had a slightly higher proportion of participants
from ethnic minority backgrounds) [29], the mean
scores for each of the subscales in our sample were very
similar, except for the awkwardness and avoidance
scores, which were somewhat lower in our sample. It is
difficult to interpret these differences; they may be due to
sampling effects, mode effects (face-to-face interview ver-
sus online survey), or they may indicate that feelings of
awkwardness and the desire to avoid cancer patients are
decreasing over time. It should be noted that levels of
avoidance as assessed in the current study are very low,
with only 4–5% of the general population anticipating
avoiding someone with cancer, although feelings of awk-
wardness were slightly higher and endorsed by 10–17%.
The demographic pattern of cancer stigma was also
similar to that found in the CASS development paper
[29], with higher levels of cancer stigma in men than
women, and among those from ethnic minority back-
grounds compared with those from White ethnic back-
grounds. To our knowledge, no other studies have
explicitly examined gender differences in public cancer
stigma, although two studies in university student sam-
ples suggest that women are less likely than men to dis-
tance themselves from patients with cancer or refuse to
help them [35, 36]. The finding that cancer stigma is
higher in men is also consistent with a study about men-
tal health stigma among US legislators that found that
men were overrepresented among legislators with high
levels of stigma (84% male versus 75% of all legislators
included in the study) [37].
There is some previous research on cancer stigma in
ethnic minority communities, although mainly in quali-
tative studies, where participants often describe cancer
as a stigmatised disease, a ‘taboo’ or as not openly dis-
cussed within their communities [38–41]. A narrative re-
view identified cancer stigma among ethnic minority
communities as a barrier to accessing cancer genetic ser-
vices [42, 43], and Black cancer patients expressed a
greater need for post-treatment information on how to
deal with stigma than White patients [44]; findings that
are indicative of greater cancer stigma in ethnic minority
communities. There may be a need for culturally sensi-
tive interventions designed especially to address stigma
in ethnic minorities.
Unlike previous findings [26], we did not find an asso-
ciation between socioeconomic status and cancer stigma,
but comparisons between these studies are difficult due
to differences in samples, stigma measures, and opera-
tionalisation of socioeconomic status. There is well-
documented socioeconomic variation in cancer risk be-
haviours and mortality [45, 46], which may affect per-
ceptions of cancer stigma. Future studies should further
examine the association between cancer stigma and so-
cioeconomic status, in particular for the specific sub-
scales of cancer stigma, such as personal responsibility
and severity attributions, and their association with can-
cer prevention and early detection.
We also found that higher stigma scores were associ-
ated with not being screened as recommended for all
three types of cancer screening. This is consistent with
previous research findings. For example, qualitative stud-
ies in the US and Australia identified cancer stigma as a
barrier to lung cancer screening and help-seeking for
possible lung cancer symptoms [47, 48]. Lung cancer
stigma was also associated with delayed help-seeking in
a quantitative US study among recently-diagnosed lung
cancer patients, even after controlling for other variables
associated with delayed presentation such as ethnicity,
smoking status, and medical distrust [13]. Unlike the
US, lung cancer screening has not yet been implemented
in the UK, and future studies may wish to explore the ef-
fect of cancer stigma on lung screening uptake, especially
because previous research suggests that public stigma of
lung cancer is greater than for other common types of
cancer, such as breast, colorectal, and skin cancer [30].
About one in ten people endorsed statements about
personal responsibility for cancer. It is estimated that
about 40% of cancers are due to lifestyle choices [49],
and public health campaigns are increasingly raising
awareness of this link between modifiable risk factors
and cancer to further the cancer prevention effort. How-
ever, an unintended consequence of this may be that
cancer could increasingly be seen as being self-inflicted.
This kind of “victim blaming” may already be happening
for lung cancer patients because of the well-known asso-
ciation with smoking [8, 50], but may become apparent
for other cancers as well once other modifiable cancer
risk factors, such as obesity, poor diet, and alcohol con-
sumption, become better known to the general public.
Ironically, increased stigma due to better awareness may
negatively impact engagement with cancer prevention
and so it is imperative for public health campaigners to
find the “sweet spot” for maximising cancer risk factor
awareness while minimising stigma [50]. Future studies
could help by monitoring the evolution of the different
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dimensions of stigma over time, in particular the per-
sonal responsibility and policy opposition dimensions.
Our study had several limitations. First, we had to re-
duce the number of items in the CASS due to space re-
strictions in the survey, but this may have lowered the
internal validity of some of the subscales. Second, the
ABACUS survey is a population-representative survey
but no response rate is recorded by the market research
agency. This means that the levels of cancer stigma re-
ported here, and the percentage endorsement of the in-
dividual items, can be generalised to the population of
English adults aged 18–70. However, the ABACUS sur-
vey was not powered to examine the association be-
tween cancer stigma and cancer screening uptake, and
the strength of the associations found here may be lim-
ited by the smaller sample sizes. In addition, due to the
small samples eligible for each of the cancer screening
programmes, we could not examine the association be-
tween the 6 separate dimensions of cancer stigma and
screening uptake. Furthermore, the items in the CASS
are about cancer in general. Previous research has
shown that some cancer types elicit more stigma than
others [30]. Different types of cancer also have different
aetiologies, and the degree to which the public is aware
of this varies, so future studies should consider trying
to unpick associations between knowledge, stigma and
behaviour for specific cancer types [1]. However, we ex-
pect that the associations found between cancer stigma
and cancer screening uptake, which were statistically
significant in both unadjusted and adjusted analyses,
would be even stronger if cancer type-specific measures
of stigma were used. Another limitation of the current
study is that the internal reliability of some of the
shortened sub scales of the CASS was quite low. Des-
pite our best efforts to create an internally reliable
shorter version of the CASS by conducting some pilot
work, we recommend that future studies use the full
set of 25 CASS items. Alternatively, more work could
be done to develop a shorter version of the CASS that
has better internal reliability, although any attempts to
shorten the CASS would necessarily be restricted by
the number of sub scales that need to be accurately
measured. Finally, this was a cross-sectional study so
no inferences about causality between cancer stigma
and cancer screening attendance can be made. Future
studies should prospectively include screening-eligible
samples that are large enough to examine differences in
screening uptake for each of the 6 dimensions of cancer
stigma, and may wish to adapt the CASS to make it
cancer-specific.
Conclusions
Cancer stigma in England is generally low, but still
exists, with some aspects more prevalent than others.
Stigma is greatest among particular population sub-
groups, including those from ethnic minority back-
grounds, and is negatively associated with cancer
screening behaviours. Our benchmark findings may
help track and reduce cancer stigma in England
over time.
Additional file
Additional file 1: Table S1. Unadjusted and adjusted odds ratios (OR),
95% confidence intervals (95% CI), and significance values for having
never been screened (vs. having been screened at least once) by total
CASS (cancer stigma) score for cervical (N = 681), breast (N = 326) and
colorectal cancer screening (N = 371). (DOCX 14 kb)
Abbreviations
ABACUS: Attitudes and Behaviour about Cancer UK Survey; BAME: Black And
Minority Ethnic; CASS: Cancer Stigma Scale; NHS: National Health Service;
NRS: National Readership Survey; OR: Odds Ratio
Acknowledgements
We would like to acknowledge the intellectual contribution that Professor
Jane Wardle made to this study before her death in October 2015.
Authors’ contributions
CV and LM conceived of the study, and CV was responsible for data
collection. CV and AG analysed the data and drafted the manuscript, with
input from LM and JW. All authors have seen and approved the final version
of the manuscript before submission.
Funding
This study was supported by a Cancer Research UK programme grant
awarded to the late Professor Jane Wardle (C1418/A14134), which also
funded Charlotte Vrinten and Ailish Gallagher. Jo Waller and Laura Marlow
are funded by Cancer Research UK award C7492/A17219. Cancer Research
UK was not involved in the design of the study; collection, analysis, or
interpretation of the results; in the writing of this manuscript; or in the
decision to submit for publication.
Availability of data and materials
Data available from the first author upon reasonable request.
Ethics approval and consent to participate
This study was approved by the UCL Research Ethics Committee (Project ID
Number: 5771/002). Since data collection was outsourced, the consent
procedure was determined by the market research company that collected
the data (Kantar TNS). Kantar TNS collect verbal consent at the start of the
Omnibus interview for the survey as a whole, including our section on
Attitudes, Behaviour, and Cancer UK Survey (ABACUS), which was recorded
as part of the interview, in line with the Market Research Society’s (MRS)
Code of Conduct for market research. At the start of the ABACUS section of
the interview, participants were informed about the nature and aims of the
ABACUS survey. They were also reminded that they could skip any questions
or sections of the survey that they did not wish to respond to, and that their
responses would be kept strictly confidential.
Consent for publication
N/A.
Competing interests
The authors declare that they have no competing interests.
Vrinten et al. BMC Cancer          (2019) 19:566 Page 8 of 10
Received: 4 December 2018 Accepted: 31 May 2019
References
1. Else-Quest N, Jackson T. Chapter 8: Cancer stigma. In: Corrigan PW, editor. The
stigma of disease and disability: understanding causes and overcoming injustices.
Washington DC: American Psychological Association; 2014. p. 165–81.
2. Agustina E, Dodd RH, Waller J, Vrinten C. Understanding middle-aged and
older adults' first associations with the word "cancer": a mixed methods
study in England. Psychooncology. 2018;27:309–15.
3. Quaife SL, Winstanley K, Robb KA, Simon AE, Ramirez AJ, Forbes LJ, et al.
Socioeconomic inequalities in attitudes towards cancer: an international
cancer benchmarking partnership study. Eur J Cancer Prev. 2015;24:253–60.
4. Weiss MG, Ramakrishna J. Stigma interventions and research for
international health. Lancet. 2006;367:536–8.
5. Jones N, Corrigan PW. Chapter 1: Understanding stigma. In: Corrigan PW,
editor. The stigma of disease and disability: understanding causes and
overcoming injustices. Washington DC: American Psychological Association;
2014. p. 9–34.
6. Goffman E. Stigma: notes on the management of spoiled identity.
Englewood Cliffs: Prentice-Hall; 1963.
7. Knapp S, Marziliano A, Moyer A. Identity threat and stigma in cancer
patients. Health Psychol Open. 2014;1(1):2055102914552281.
8. Lebel S, Devins GM. Stigma in cancer patients whose behavior may have
contributed to their disease. Future Oncol. 2008;4:717–33.
9. Marlow LA, Waller J, Wardle J. Variation in blame attributions across
different cancer types. Cancer Epidemiol Biomark Prev. 2010;19:1799–805.
10. Else-Quest NM, LoConte NK, Schiller JH, Hyde JS. Perceived stigma, self-
blame, and adjustment among lung, breast and prostate cancer patients.
Psychol Health. 2009;24:949–64.
11. Chambers SK, Dunn J, Occhipinti S, Hughes S, Baade P, Sinclair S, et al. A
systematic review of the impact of stigma and nihilism on lung cancer
outcomes. BMC Cancer. 2012;12:184.
12. Ahmad AS, Ormiston-Smith N, Sasieni PD. Trends in the lifetime risk of
developing cancer in Great Britain: comparison of risk for those born from
1930 to 1960. Br J Cancer. 2015;112:943–7.
13. Carter-Harris L, Hermann CP, Schreiber J, Weaver MT, Rawl SM. Lung cancer
stigma predicts timing of medical help-seeking behavior. Oncol Nurs
Forum. 2014;41:E203–10.
14. Miles A, Rainbow S, von Wagner C. Cancer fatalism and poor self-rated
health mediate the association between socioeconomic status and uptake
of colorectal cancer screening in England. Cancer Epidemiol Biomark Prev.
2011;20:2132–40.
15. Ndukwe EG, Williams KP, Sheppard V. Knowledge and perspectives of breast
and cervical cancer screening among female African immigrants in the
Washington D.C. metropolitan area. J Cancer Educ. 2013;28:748–54.
16. Michielutte R, Dignan MB, Sharp PC, Boxley J, Wells HB. Skin cancer
prevention and early detection practices in a sample of rural women. Prev
Med. 1996;25:673–83.
17. Moser RP, Arndt J, Han PK, Waters EA, Amsellem M, Hesse BW. Perceptions
of cancer as a death sentence: prevalence and consequences. J Health
Psychol. 2014;19:1518–24.
18. Corrigan P. How stigma interferes with mental health care. Am Psychol.
2004;59:614–25.
19. Villatoro AP, DuPont-Reyes MJ, Phelan JC, Painter K, Link BG. Parental
recognition of preadolescent mental health problems: does stigma matter?
Soc Sci Med. 2018;216:88–96.
20. Clement S, Schauman O, Graham T, Maggioni F, Evans-Lacko S,
Bezborodovs N, et al. What is the impact of mental health-related stigma
on help-seeking? A systematic review of quantitative and qualitative studies.
Psychol Med. 2015;45:11–27.
21. Gary FA. Stigma: barrier to mental health care among ethnic minorities.
Issues Ment Health Nurs. 2005;26:979–99.
22. Marcell AV, Morgan AR, Sanders R, Lunardi N, Pilgrim NA, Jennings JM, et al.
The socioecology of sexual and reproductive health care use among young
urban minority males. J Adolesc Health. 2017;60:402–10.
23. Rade DA, Crawford G, Lobo R, Gray C, Brown G. Sexual health help-seeking
behavior among migrants from sub-Saharan Africa and South East Asia
living in high income countries: a systematic review. Int J Environ Res Public
Health. 2018;15:E1311.
24. Vaughn-Sandler V, Sherman C, Aronsohn A, Volk ML. Consequences of
perceived stigma among patients with cirrhosis. Dig Dis Sci. 2014;59:681–6.
25. Herrmann LK, Welter E, Leverenz J, Lerner AJ, Udelson N, Kanetsky C, et al. A
systematic review of dementia-related stigma research: can we move the
stigma dial? Am J Geriatr Psychiatry. 2018;26:316–31.
26. O'Connor M, O'Leary E, Waller J, Gallagher P, Martin CM, O’Leary JJ, et al.
Socio-economic variations in anticipated adverse reactions to testing HPV
positive: implications for the introduction of primary HPV-based cervical
screening. Prev Med. 2018;115:90–6.
27. Myrick JG. Public perceptions of celebrity cancer deaths: how identification
and emotions shape cancer stigma and behavioral intentions. Health
Commun. 2017;32:1385–95.
28. United States Census Bureau. Quick Facts. Available from: https://www.census.
gov/quickfacts/fact/table/US/PST045217. Accessed 6 June 2019.
29. Marlow LA, Wardle J. Development of a scale to assess cancer stigma in the
non-patient population. BMC Cancer. 2014;14:285.
30. Marlow LA, Waller J, Wardle J. Does lung cancer attract greater stigma than
other cancer types? Lung Cancer. 2015;88:104–7.
31. Murphy PJ, Marlow LAV, Waller J, Vrinten C. What is it about a cancer
diagnosis that would worry people? A population-based survey of adults in
England. BMC Cancer. 2018;18:86–95.
32. Office for National Statistics. 2011 Census questionnaire for England.
Available from: https://www.ons.gov.uk/census/2011census/
howourcensusworks/howwetookthe2011census/
howwecollectedtheinformation/questionnairesdeliverycompletionandreturn.
Accessed 6 June 2019.
33. National Readership Survey. Social Grade. Available from http://www.nrs.co.
uk/nrs-print/lifestyle-and-classification-data/social-grade/. Accessed 6 June
2019.
34. Korn EL, Graubard BI. Epidemiologic studies utilizing surveys: accounting for
the sampling design. Am J Public Health. 1991;81:1166–73.
35. Schulte A. Consensus versus disagreement in disease-related stigma: a
comparison of reactions to AIDS and cancer patients. Sociol Perspect. 2002;
45:81–104.
36. Mosher CE, Danoff-Burg S. Death anxiety and cancer-related stigma: a terror
management analysis. Death Studies. 2007;31:885–907.
37. Purtle J, Le-Scherban F, Wang X, Shattuck PT, Proctor EK, Brownson RC.
Audience segmentation to disseminate behavioral health evidence to
legislators: an empirical clustering analysis. Implement Sci. 2018;13:121.
38. Randhawa G, Owens A. The meanings of cancer and perceptions of cancer
services among south Asians in Luton, UK. Br J Cancer. 2004;91:62–8.
39. Thomas VN, Saleem T, Abraham R. Barriers to effective uptake of cancer
screening among black and minority ethnic groups. Int J Palliat Nurs. 2005;
11:562–71.
40. Bedi M, Devins GM. Cultural considerations for south Asian women with
breast cancer. J Cancer Surviv. 2016;10:31–50.
41. Jones CE, Maben J, Lucas G, Davies EA, Jack RH, Ream E. Barriers to early
diagnosis of symptomatic breast cancer: a qualitative study of black African,
black Caribbean and white British women living in the UK. BMJ Open. 2015;
5:e006944.
42. Allford A, Qureshi N, Barwell J, Lewis C, Kai J. What hinders minority ethnic
access to cancer genetics services and what may help? Eur J Human Genet.
2014;22:866–74.
43. Hann KEJ, Freeman M, Fraser L, Waller J, Sanderson SC, Rahman B, et al.
Awareness, knowledge, perceptions, and attitudes towards genetic testing
for cancer risk among ethnic minority groups: a systematic review. BMC
Public Health. 2017;17:503.
44. Asare M, Peppone LJ, Roscoe JA, Kleckner IR, Mustian KM, Heckler CE, et al.
Racial differences in information needs during and after cancer treatment: a
nationwide, longitudinal survey by the University of Rochester cancer
center national cancer institute community oncology research program. J
Cancer Educ. 2018;33:95–101.
45. Lian M, Schootman M, Doubeni CA, Park Y, Major JM, Stone RA, et al.
Geographic variation in colorectal cancer survival and the role of small-area
socioeconomic deprivation: a multilevel survival analysis of the NIH-AARP
diet and health study cohort. Am J Epidemiol. 2011;174:828–38.
46. Sauer AG, Siegel RL, Jemal A, Fedewa SA. Updated review of prevalence of
major risk factors and use of screening tests for cancer in the United States.
Cancer Epidemiol Biomark Prev. 2017;26:1192–208.
47. Carter-Harris L, Ceppa DP, Hanna N, Rawl SM. Lung cancer screening: what
do long-term smokers know and believe? Health Expect. 2017;20:59–68.
Vrinten et al. BMC Cancer          (2019) 19:566 Page 9 of 10
48. Crane M, Scott N, O'Hara BJ, Aranda S, Lafontaine M, Stacey I, et al.
Knowledge of the signs and symptoms and risk factors of lung cancer in
Australia: mixed methods study. BMC Public Health. 2016;16:508.
49. Parkin DM, Boyd L, Walker LC. 16. The fraction of cancer attributable to
lifestyle and environmental factors in the UK in 2010. Br J Cancer. 2011;
105(Suppl 2):S77–81.
50. Riley KE, Ulrich MR, Hamann HA, Ostroff JS. Decreasing smoking but
increasing stigma? Anti-tobacco campaigns, public health, and cancer care.
AMA J Ethics. 2017;19:475–85.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Vrinten et al. BMC Cancer          (2019) 19:566 Page 10 of 10
